NO20031909D0 - Selvemulgerende, orale doseringsformuleringer av pyranon protease-inhibitorer - Google Patents

Selvemulgerende, orale doseringsformuleringer av pyranon protease-inhibitorer

Info

Publication number
NO20031909D0
NO20031909D0 NO20031909A NO20031909A NO20031909D0 NO 20031909 D0 NO20031909 D0 NO 20031909D0 NO 20031909 A NO20031909 A NO 20031909A NO 20031909 A NO20031909 A NO 20031909A NO 20031909 D0 NO20031909 D0 NO 20031909D0
Authority
NO
Norway
Prior art keywords
self
oral dosage
protease inhibitors
dosage formulations
pyranone protease
Prior art date
Application number
NO20031909A
Other languages
English (en)
Other versions
NO20031909L (no
Inventor
Shirlynn Chen
Jocelyn A Gunn
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of NO20031909D0 publication Critical patent/NO20031909D0/no
Publication of NO20031909L publication Critical patent/NO20031909L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medical Informatics (AREA)
  • Dispersion Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Cosmetics (AREA)
NO20031909A 2000-10-31 2003-04-29 Selvemulgerende, orale doseringsformuleringer av pyranon protease-inhibitorer NO20031909L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24443400P 2000-10-31 2000-10-31
PCT/US2001/048683 WO2002036110A2 (en) 2000-10-31 2001-10-30 Oral self-emulsifying formulations of pyranone protease inhibitors

Publications (2)

Publication Number Publication Date
NO20031909D0 true NO20031909D0 (no) 2003-04-29
NO20031909L NO20031909L (no) 2003-05-22

Family

ID=22922748

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031909A NO20031909L (no) 2000-10-31 2003-04-29 Selvemulgerende, orale doseringsformuleringer av pyranon protease-inhibitorer

Country Status (29)

Country Link
US (1) US6555558B2 (no)
EP (1) EP1333810B1 (no)
JP (1) JP4298998B2 (no)
KR (1) KR100847679B1 (no)
CN (1) CN1240437C (no)
AT (1) ATE381922T1 (no)
AU (2) AU3091802A (no)
BG (1) BG107728A (no)
BR (1) BR0114969A (no)
CA (1) CA2424596C (no)
CZ (1) CZ20031407A3 (no)
DE (1) DE60132103T2 (no)
DK (1) DK1333810T3 (no)
EA (1) EA006759B1 (no)
EC (1) ECSP034572A (no)
EE (1) EE200300201A (no)
ES (1) ES2298286T3 (no)
HR (1) HRP20030339A2 (no)
HU (1) HUP0301487A2 (no)
IL (2) IL154983A0 (no)
MX (1) MXPA03003795A (no)
NO (1) NO20031909L (no)
NZ (1) NZ526169A (no)
PL (1) PL365627A1 (no)
SK (1) SK6572003A3 (no)
UA (1) UA78689C2 (no)
WO (1) WO2002036110A2 (no)
YU (1) YU32103A (no)
ZA (1) ZA200302389B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4994043B2 (ja) * 2004-01-21 2012-08-08 エランコ・アニマル・ヘルス・アイルランド・リミテッド ミトラタピデ経口用溶液
US20050256097A1 (en) * 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
JP4373427B2 (ja) * 2005-11-15 2009-11-25 エフ．ホフマン−ラ ロシュ アーゲー 電気的滴下監視
EP1957053A4 (en) * 2005-11-17 2012-03-28 Bioavailability Inc BIOKOMPATIBLE LATENT EMULSIFICATORS
JP2009542605A (ja) * 2006-07-06 2009-12-03 アレス トレーディング ソシエテ アノニム アニリノ−ピリミジンの経口医薬組成物、その製法、及びその使用
JP2010526848A (ja) * 2007-05-11 2010-08-05 エフ．ホフマン−ラ ロシュ アーゲー 難溶性薬物用の医薬組成物
WO2008142090A1 (en) * 2007-05-23 2008-11-27 Boehringer Ingelheim International Gmbh Self-emulsifying formulation of tipranavir for oral administration
WO2009084036A2 (en) * 2007-12-20 2009-07-09 Matrix Laboratories Limited Composition for treatment of viral infections
WO2012010942A2 (en) * 2010-07-22 2012-01-26 Lupin Limited Novel pharmaceutical composition(s) of hiv protease inhibitor(s)
MY158809A (en) * 2010-09-22 2016-11-15 Craun Res Sdn Bhd Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
US20140128431A1 (en) 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
US20130302414A1 (en) * 2012-05-07 2013-11-14 Bristol-Myers Squibb Company Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
NZ708272A (en) 2013-01-22 2020-07-31 Hoffmann La Roche Pharmaceutical composition with improved bioavailability
US20160000799A1 (en) 2013-02-21 2016-01-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
JP6605047B2 (ja) 2015-05-28 2019-11-13 ドクター・レディーズ・ラボラトリーズ・リミテッド 疼痛治療のためのセレコキシブの経口用組成物
JP7217700B2 (ja) 2016-09-13 2023-02-03 アラーガン、インコーポレイテッド 安定化非タンパク質クロストリジウム毒素組成物
CN114681470A (zh) 2020-12-28 2022-07-01 雷迪博士实验室有限公司 治疗疼痛的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1033128T4 (da) * 1993-09-28 2012-03-19 Scherer Gmbh R P Blød gelatinekapselfremstilling
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
KR0167613B1 (ko) * 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제 조성물
US6008228A (en) * 1995-06-06 1999-12-28 Hoffman-La Roche Inc. Pharmaceutical compositions containing proteinase inhibitors
DK0999838T3 (da) * 1997-07-29 2002-07-08 Upjohn Co Selv-emulgerende formulering for lipofile forbindelser
JP4524367B2 (ja) * 1997-07-29 2010-08-18 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 自己乳化性処方形態の酸性親油性化合物用の医薬組成物
HK1040625B (zh) * 1998-11-04 2005-04-01 法玛西雅厄普约翰美国公司 用於改善替普拉那维的药物动力学的方法

Also Published As

Publication number Publication date
DE60132103T2 (de) 2008-04-17
US6555558B2 (en) 2003-04-29
CZ20031407A3 (cs) 2003-09-17
EA006759B1 (ru) 2006-04-28
EP1333810B1 (en) 2007-12-26
WO2002036110A9 (en) 2003-09-18
JP4298998B2 (ja) 2009-07-22
EE200300201A (et) 2003-08-15
MXPA03003795A (es) 2003-08-20
ES2298286T3 (es) 2008-05-16
CN1240437C (zh) 2006-02-08
HRP20030339A2 (en) 2005-04-30
NZ526169A (en) 2005-12-23
JP2004512362A (ja) 2004-04-22
HK1060523A1 (en) 2004-08-13
SK6572003A3 (en) 2003-10-07
BR0114969A (pt) 2003-12-09
ZA200302389B (en) 2004-04-23
EA200300481A1 (ru) 2003-10-30
WO2002036110A3 (en) 2003-05-08
CN1471387A (zh) 2004-01-28
HUP0301487A2 (hu) 2003-11-28
KR20030048097A (ko) 2003-06-18
KR100847679B1 (ko) 2008-07-23
WO2002036110A2 (en) 2002-05-10
AU3091802A (en) 2002-05-15
CA2424596C (en) 2010-06-29
CA2424596A1 (en) 2002-05-10
US20020115690A1 (en) 2002-08-22
ATE381922T1 (de) 2008-01-15
IL154983A (en) 2006-12-31
IL154983A0 (en) 2003-10-31
YU32103A (sh) 2006-05-25
AU2002230918B2 (en) 2006-12-14
DE60132103D1 (de) 2008-02-07
UA78689C2 (en) 2007-04-25
PL365627A1 (en) 2005-01-10
EP1333810A2 (en) 2003-08-13
ECSP034572A (es) 2003-05-26
NO20031909L (no) 2003-05-22
BG107728A (bg) 2004-01-30
DK1333810T3 (da) 2008-02-04

Similar Documents

Publication Publication Date Title
ATE296619T1 (de) Feste orale dosierungsform von simethicon
FR2804025B1 (fr) Compositions pharmaceutiques stabilisees
EP1383518A4 (en) ORAL DELIVERY OF MACROMOLECULES
ITTO20010005A0 (it) Formulazione farmaceutica.
HUP0400202A3 (en) Imidazolidindion derivatives having metalloproteinase inhibitor effect, their use and pharmaceutical compositions containing them
NO20042807L (no) Farmasoytiske sammensetninger som innbefatter aktive vitamin D forbindelser
NO20024528L (no) Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen
NO20030055L (no) Colchinolderivater som angiogenese inhibitorer
NO20033556L (no) Farmasöytiske formuleringer
NO20026037L (no) Sötvareprodukt som inneholder aktive bestanddeler
PT1253932E (pt) Composicoes farmaceuticas de toxina botulinica
CY2013011I1 (el) Μεθοδος χορηγησης διφωσφονικων
MXPA03000059A (es) Derivados de pirazol.
NO20031672D0 (no) Aza- og polyaza-naftalenylkarboksamider for anvendelse som HIV-integraseinhibitorer
NO20030867D0 (no) Hydroksamderivater anvendelig som deacetylaseinhibitorer
NO20042739L (no) Farmasoytiske sammensetninger av 5,6,14-triazatetracyklo(10.3.1.0(2,11).0(4,9))-heksadeca-2(11)3,5,7,9-pentan
DK1333810T3 (da) Orale selvemulgerende doseringsformuleringer af pyranon-protease-inhibitorer
NO20040125L (no) Enterale formuleringer
IS6508A (is) Lyfjasamsetningar af glycogen fosfórýlasa lötum
EE05020B1 (et) Glburiidi ravimkoostis
HUP0400193A3 (en) Imidazolindion derivatives as metalloproteinase inhibitors, their use and pharmaceutical compositions containing them
DE10196204T1 (de) Orale Vorrichtungen
IS6021A (is) Lyfjasamsetningar sem innihalda sítalópram
NO20031095D0 (no) Farmasöytiske sammensetninger
NO20040857L (no) Ny oral forlenget frigivelses doseringsform.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application